Skip to main content

Advertisement

Table 2 Overview of studies in systematic review, grouped according to outcome data from virology and immunology response and serious drug- related AEs

From: Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials

Authors and publish time Virology and immunologic response Serious drug- related AEs
Experiment group,  % (n/N) Control group, n (%) Experiment group, n (%) Control group, n (%)
Jan van Lunzen et al. 2012. [20] 10 mg: 91 % (48/53) 25 mg: 88 % (45/51) 50 mg: 90 % (46/5150) EFV (600 mg): 82 % (41/50) 0 2 % (1/50)
Pedro Cahn et al. 2013. [23] 50 mg: 71 % (251/354,378) RAL (400 mg): 64 % (230/414) 1 % (2/378) 1 % (4/414)
Francois Raffi et al. 2013. [21] 50 mg: 88 % (361/411) RAL (400 mg): 85 % (351/411) <1 % (3/411) 1 % (5/411)
S. Walmsley et al. 2013. [22] 50 mg: 88 % (364/414) RAL (400 mg): 81 % (338/419) <1 % (1/414) 2 % (8/419)
  1. DTG dolutegravir, S/GSK1349572; RAL raltegravir; EFV efavirenz